DBV Technologies (DBVT) Net Income (2020 - 2026)
DBV Technologies (DBVT) posted quarterly Net Income of -$50.4 million for Q2 2026, down 20.29% year-on-year from -$63.2 million in Q2 2025, and down 5.88% on a QoQ basis from -$47.6 million in Q1 2026.
DBV Technologies (DBVT) Net Income (2020 - 2026) Analysis & Trends
DBV Technologies (DBVT) has reported Net Income for 7 consecutive years, with -$50.4 million the latest figure, recorded in Q2 2026.
- Quarterly Net Income fell 20.29% year-over-year to -$50.4 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was -$176.0 million (down 43.72% YoY) and the FY2025 annual result came in at -$146.9 million, down 28.99% from the prior year.
- Net Income fell to -$50.4 million in Q2 2026 per DBVT's latest filing, from -$47.6 million in the prior quarter.
- Over the last five years, Net Income for DBVT reached as high as -$11.2 million in Q4 2023 and fell as low as -$50.4 million in Q2 2026.
- A 5-year average of -$29.3 million and a median of -$27.2 million in 2024 frame the typical range for Net Income.
- Annual changes were most pronounced in 2022 — Net Income slumped 187.02% — and 2023, when it jumped 71.49%.
- Year by year, Net Income stood at -$39.2 million in 2022, then soared by 71.49% to -$11.2 million in 2023, then slumped by 105.75% to -$23.0 million in 2024, then slumped by 94.78% to -$44.8 million in 2025, then slipped by 12.43% to -$50.4 million in 2026.
- According to Business Quant data, Net Income over the past three periods registered -$50.4 million, -$47.6 million, and -$44.8 million for Q2 2026, Q1 2026, and Q4 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -37.09 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 227.36 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -3.31 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 1.03 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 727.20 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | -26.94 Mn |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 362.00 Mn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -453.82 Mn |
| 10 | DBV Technologies | 267.50 Mn | 92.60 Mn | - | -50.40 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -50.40 Mn |
| Mar 31, 2026 | -47.60 Mn |
| Dec 31, 2025 | -44.83 Mn |
| Sep 30, 2025 | -33.16 Mn |
| Jun 30, 2025 | -41.90 Mn |
| Mar 31, 2025 | -27.10 Mn |
| Dec 31, 2024 | -23.02 Mn |
| Sep 30, 2024 | -30.44 Mn |
| Jun 30, 2024 | -33.12 Mn |
| Mar 31, 2024 | -27.35 Mn |
| Dec 31, 2023 | -11.19 Mn |
| Sep 30, 2023 | -16.74 Mn |
| Jun 30, 2023 | -24.24 Mn |
| Mar 31, 2023 | -20.56 Mn |
| Dec 31, 2022 | -39.24 Mn |
| Sep 30, 2022 | -17.29 Mn |
| Jun 30, 2022 | -23.04 Mn |
| Mar 31, 2022 | -16.71 Mn |
| Dec 31, 2021 | -13.67 Mn |
| Sep 30, 2021 | -24.03 Mn |